Review: Experience of Randomized Trials Without Surgical Controls

  • D. C. Tormey
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 96)


The trials presented in this section deal with four major issues in the adjuvant treatment of breast cancer: the optimal duration of therapy, treatment intensity, implications regarding drug schedule, and the role of combining tamoxifen with chemotherapy.


Clin Oncol Advanced Breast Cancer Surgical Control Chemohormonal Therapy Eastern Cooperative Oncology Group Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holland JF (1983) Breaking the cure barrier. J Clin Oncol 1: 75–90PubMedGoogle Scholar
  2. 2.
    Muss HB, White DR, Cooper R, Richards II F, Spurr CL (1977) Combination chemotherapy in advanced breast cancer. Arch Intern Med 137: 1711–1714PubMedCrossRefGoogle Scholar
  3. 3.
    Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group trial. Cancer 50: 1235–1244PubMedCrossRefGoogle Scholar
  4. 4.
    Tormey DC, Gelman R, Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer: An Eastern Cooperative Oncology Group trial. Am J Clin Oncol 6: 1–8Google Scholar
  5. 5.
    Engelsman E, Mouridsen HT, Palshof T, Sylvester R (1981) CMF vs CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC study. Rev Endocrine Related Cancer [Suppl] 9: 427–438Google Scholar
  6. 6.
    Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Cancer Clin Trials 5: 33–39Google Scholar
  7. 7.
    Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, Band PR (1976) Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882–1886Google Scholar
  8. 8.
    DeLena M, Brambilla C, Morbito A, Bonadonna G (1975) Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35: 1108–1115CrossRefGoogle Scholar
  9. 9.
    Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J, Holland JF (to be published) A comparison of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer — a cancer and leukemia group B study. Am J Clin OncolGoogle Scholar
  10. 10.
    Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13–20PubMedCrossRefGoogle Scholar
  11. 11.
    Osborne CK, Blodt DH, Clark GM, Trent JM (1983) Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585PubMedGoogle Scholar
  12. 12.
    Jordan VC, Dix CJ, Allen KE (1979) The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune and Stratton, New York, pp 19–26Google Scholar
  13. 13.
    Tormey DC, Jordan VC (to be published) Adjuvant chemotherapy and chemohormonal therapy in postoperative N+ patients. In: Breast cancer — Therapeutic modalities, current and futureGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • D. C. Tormey
    • 1
  1. 1.Department of Human OncologyK4/666, Clinical Science CenterMadisonUSA

Personalised recommendations